CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-08-31 | Novak Rodger Chief Executive Officer | Sale | −14,617 | $20.87 | $305K | 1,148,007 |
| 2017-08-30 | Novak Rodger Chief Executive Officer | Exercise or conversion | +5,722 | $1.81 | $10K | 1,220,727 |
| 2017-08-30 | Novak Rodger Chief Executive Officer | Sale | −58,103 | $20.31 | $1.2M | 1,162,624 |
| 2017-08-30 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −5,722 | 44,679 | ||
| 2017-08-28 | Novak Rodger Chief Executive Officer | Exercise or conversion | +17,692 | $1.81 | $32K | 1,232,697 |
| 2017-08-28 | Novak Rodger Chief Executive Officer | Sale | −17,692 | $20.06 | $355K | 1,215,005 |
| 2017-08-28 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −17,692 | 50,401 | ||
| 2017-06-22 | Novak Rodger Chief Executive Officer | Exercise or conversion | +10,825 | $1.81 | $20K | 1,225,830 |
| 2017-06-22 | Novak Rodger Chief Executive Officer | Sale | −10,825 | $15.37 | $166K | 1,215,005 |
| 2017-06-22 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −10,825 | 68,093 | ||
| 2017-06-21 | Novak Rodger Chief Executive Officer | Exercise or conversion | +11,578 | $1.81 | $21K | 1,266,583 |
| 2017-06-21 | Novak Rodger Chief Executive Officer | Sale | −11,578 | $15.02 | $174K | 1,215,005 |
| 2017-06-21 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −11,578 | 78,918 | ||
| 2017-06-20 | Novak Rodger Chief Executive Officer | Exercise or conversion | +3,252 | $1.81 | $6K | 1,218,257 |
| 2017-06-20 | Novak Rodger Chief Executive Officer | Sale | −3,252 | $15.00 | $49K | 1,215,005 |
| 2017-06-20 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −3,252 | 90,496 | ||
| 2017-06-19 | Novak Rodger Chief Executive Officer | Exercise or conversion | +15,392 | $1.81 | $28K | 1,230,397 |
| 2017-06-19 | Novak Rodger Chief Executive Officer | Sale | −15,392 | $15.00 | $231K | 1,215,005 |
| 2017-06-19 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −15,392 | 93,748 | ||
| 2017-06-15 | Novak Rodger Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +270,000 | 270,000 |
Page 4 of 6 · 116 trades